Controlled Substance Importer Application: Fisher Clinical Services

FR: Drug Enforcement Administration

Published April 1st, 2026

Detected April 1st, 2026

Summary

The Drug Enforcement Administration published a notice that Fisher Clinical Services, Inc. applied to be registered as an importer of a Schedule I controlled substance (3,4-Methylenedioxymethamphetamine, Drug Code 7405). The company plans to use the substance for clinical trials only. Registered manufacturers and applicants may submit comments or objections on or before May 1, 2026.

View original document View source feed page

What changed

The DEA published notice that Fisher Clinical Services, Inc. of Breinigsville, Pennsylvania applied on March 11, 2026 for registration as a controlled substance importer under 21 CFR 1301.34(a). The application covers one Schedule I substance: 3,4-Methylenedioxymethamphetamine (MDMA, Drug Code 7405). The company proposes to import the substance solely for use in clinical trials, with no authorization for commercial sale of FDA-approved or non-approved finished dosage forms.

Registered bulk manufacturers of the affected controlled substance class and other interested parties have 30 days from publication (until May 1, 2026) to submit electronic comments or written objections through regulations.gov, or to request a hearing. Requests for hearings must be sent to the DEA Hearing Clerk/OALJ and DEA Federal Register Representative at Springfield, Virginia. No compliance deadline applies to this notice as it concerns an application rather than an existing obligation.

What to do next

Review the importer application details for Fisher Clinical Services at the supplementary information address
Submit electronic comments or objections through regulations.gov by May 1, 2026 if applicable
File written request for hearing to DEA Hearing Clerk if wishing to contest the application

Source document (simplified)

Notice

Importer of Controlled Substances Application: Fisher Clinical Services, Inc.

A Notice by the Drug Enforcement Administration on 04/01/2026

This document has a comment period that ends in 30 days.
(05/01/2026) View Comment Instructions
PDF
Document Details
Document Dates

- Table of Contents

Public Comments
Regulations.gov Data

- Sharing

Print
Other Formats
Public Inspection Published Document: 2026-06258 (91 FR 16244) Document Headings ###### Department of Justice

Drug Enforcement Administration

[Docket No. DEA-1688]

AGENCY:

Drug Enforcement Administration, Justice.

ACTION:

Notice of application.

SUMMARY:

Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.

DATES:

Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on or objections to the issuance of the proposed registration on or before May 1, 2026. Such persons may also file a written request for a hearing on the application on or before May 1, 2026.

ADDRESSES:

The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ, 8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW, 8701 Morrissette Drive, Springfield, Virginia ( printed page 16245) 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration, Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.

SUPPLEMENTARY INFORMATION:

In accordance with 21 CFR 1301.34(a), this is notice that on March 11, 2026, Fisher Clinical Services, Inc., 700A-C Nestle Way, Breinigsville, Pennsylvania 18031-1522, applied to be registered as an importer of the following basic class(es) of controlled substance(s):

| Controlled substance | Drug code | Schedule |
| --- | --- | --- |
| 3,4-Methylenediox-methamphetamine | 7405 | I |
The company plans to import the listed controlled substance(s) for use in clinical trials only. No other activity for this drug code is authorized for this registration.

Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved finished dosage forms for commercial sale.

Thomas Prevozink,

Deputy Assistant Administrator.

[FR Doc. 2026-06258 Filed 3-31-26; 8:45 am]

BILLING CODE P

Published Document: 2026-06258 (91 FR 16244)